ClinicalTrials.gov
public full text
Public Domain
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
The goal of this clinical trial is to study the safety and feasibility of anti- Mesothelin Chimeric Antigen Receptor T-Cell (MESO CAR-T cells) therapy for Refractory-Relapsed Ovarian Cancer
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.#864134
- MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer#1010230
- CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas#195329
- Is platinum the new gold? Re-evaluating platinum's enduring role and future potential in the era of novel ovarian cancer therapies#922955
- Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy#851520
Record · ID 864961
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive